Show simple item record

dc.contributor.authorNissinen, Tuuli
dc.date.accessioned2020-12-07T13:04:20Z
dc.date.available2020-12-07T13:04:20Z
dc.date.issued2020
dc.identifier.isbn978-951-39-8468-7
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/72997
dc.description.abstractMuscle wasting, occurring e.g. in cancer, is associated with poor prognosis, and cancer treatments may even exacerbate the wasting. The prevention of muscle wasting has improved survival in preclinical cancer models, but the mechanisms are poorly understood. The purpose of this dissertation was to study the molecular and physiological effects of different wasting conditions and their treatment by myostatin/activin blocking. The effects of myostatin/activin blocking were studied in (1) doxorubicin (DOX) chemotherapy-treated mice, (2) tumour-bearing (TB) mice, and (3) fasted and inactive mice. Myostatin/activin blocking prevented muscle wasting in DOX-treated and TB mice. In TB mice, this was associated with improved survival, but not when myostatin/activin blocking was used to increase muscle mass only before cancer. Myostatin/activin blocking also restored bone density in DOX-treated mice, but did not counteract the impaired running capacity and the decreased physical activity in DOX-treated and TB mice, respectively. Muscle protein synthesis was decreased by DOX and restored by myostatin/activin blocking in skeletal muscle, but not in the heart. The transcriptomic responses to DOX and myostatin/activin blocking were also larger in skeletal muscle than in the heart. Muscle protein synthesis was also decreased in TB mice. This was associated with reduced mTORC1 signalling and decreased colocalization of mTOR with lysosomes, which were restored by myostatin/activin blocking. Myostatin/activin blocking also induced muscle protein synthesis in healthy mice independent of alterations in physical activity and food intake and increased the amount of mTOR colocalised with lysosomes. This study shows that prevention of muscle wasting by myostatin/activin blocking improves survival in experimental cancer and has other beneficial effects beyond skeletal muscle in chemotherapy and cancer. In addition, maintaining muscle mass may be more beneficial in terms of survival than having a larger muscle mass before the cachectic stimulus. Finally, muscle protein synthesis and mTORC1 signalling induced by myostatin/activin blocking may be mediated via increased mTOR-lysosome colocalisation in healthy and cachectic muscles. This dissertation contributes to the cachexia research with novel results that may advance the development of strategies to prevent or treat cachexia.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherJyväskylän yliopisto
dc.relation.ispartofseriesJYU dissertations
dc.relation.haspart<b>Artikkeli I:</b> Nissinen, T., Degerman, J., Räsänen, M., Poikonen, A. R., Koskinen, S., Mervaala, E., . . . Hulmi, J. (2016). Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. <i>Scientific Reports, 6, 32695.</i> <a href="https://doi.org/10.1038/srep32695"target="_blank"> DOI: 10.1038/srep32695</a>
dc.relation.haspart<b>Artikkeli II:</b> Hulmi, J., Nissinen, T., Räsänen, M., Degerman, J., Lautaoja, J., Hemanthakumar, K. A., . . . Kivelä, R. (2018). Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. <i>Journal of Cachexia, Sarcopenia and Muscle, 9 (2), 417-432.</i> <a href="https://doi.org/10.1002/jcsm.12265"target="_blank"> DOI: 10.1002/jcsm.12265</a>
dc.relation.haspart<b>Artikkeli III:</b> Nissinen, T., Hentilä, J., Penna, F., Lampinen, A., Lautaoja, J., Fachada, V., . . . Hulmi, J. (2018). Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. <i>Journal of Cachexia, Sarcopenia and Muscle, 9 (3), 514-529.</i> <a href="https://doi.org/10.1002/jcsm.12310"target="_blank"> DOI: 10.1002/jcsm.12310</a>
dc.relation.haspart<b>Artikkeli IV:</b> Nissinen, T.A., Hentilä, J., Fachada, V., Lautaoja, J.H., Pasternack, A., Ritvos, O., Kivelä, R. & Hulmi, J.J. Muscle Follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting. <i>In revision.</i>
dc.rightsIn Copyright
dc.subjectsyöpätaudit
dc.subjectmolekyylit
dc.subjectlääkehoito
dc.subjecthiiret
dc.subjectfyysinen aktiivisuus
dc.subjectluuntiheys
dc.subjectjuoksu
dc.subjectlihasmassa
dc.subjectlihaskato
dc.subjectkakeksia
dc.subjectmyostatiinit
dc.subjectkemoterapia
dc.subjectluurankolihakset
dc.subjectproteiinisynteesi
dc.subjectaktiviinit
dc.subjectactivin
dc.subjectcancer cachexia
dc.subjectchemotherapy
dc.subjectmuscle wasting
dc.subjectmyostatin
dc.subjectphysical activity
dc.subjectprotein synthesis
dc.subjectskeletal muscle
dc.subject.otheractivinen
dc.subject.othercancer cachexiaen
dc.subject.otherchemotherapyen
dc.subject.othermuscle wastingen
dc.subject.othermyostatinen
dc.subject.otherprotein synthesisen
dc.subject.otheraktiviinifi
dc.subject.otherkakeksiafi
dc.subject.otherkemoterapiafi
dc.subject.otherlihaskatofi
dc.subject.othermyostatiinifi
dc.subject.otherproteiinisynteesifi
dc.titleMolecular and physiological effects of muscle wasting and its treatment by blocking myostatin and activins
dc.typeDiss.
dc.identifier.urnURN:ISBN:978-951-39-8468-7
dc.relation.issn2489-9003
dc.rights.copyright© The Author & University of Jyväskylä
dc.rights.accesslevelopenAccess
dc.type.publicationdoctoralThesis
dc.subject.ysocancerous diseasesen
dc.subject.ysomusclesen
dc.subject.ysophysical activityen
dc.subject.ysosyöpätauditfi
dc.subject.ysolihaksetfi
dc.subject.ysofyysinen aktiivisuusfi
dc.format.contentfulltext
dc.rights.urlhttp://rightsstatements.org/page/InC/1.0/?language=en
dc.date.digitised


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

In Copyright
Except where otherwise noted, this item's license is described as In Copyright